Analyst Ratings for NxStage Medical (NXTM) [Buys]
NXTM Rating Summary
NXTM Price Target Summary
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$20.78 (+55.2%)
Avg. $ Target:
$20.78 (+55.2%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/20/2012 | ThinkEquity | New Coverage | Buy (N/A) |
22.00 (N/A) |
15.27 | 13.39 | -12.31% | Details |
| 11/17/2011 | Piper Jaffray | New Coverage | Overweight (N/A) |
24.00 (N/A) |
19.59 | 13.39 | -31.65% | Details |
| 6/10/2011 | JPMorgan | Upgrade | Overweight (N/A) |
N/A (N/A) |
17.85 | 13.39 | -24.99% | Details |
| 5/2/2011 | Stephens | New Coverage | Overweight (N/A) |
N/A (N/A) |
24.50 | 13.39 | -45.35% | Details |
| 3/16/2011 | WJB Capital | New Coverage | Buy (N/A) |
N/A (N/A) |
19.70 | 13.39 | -32.03% | Details |
| 12/17/2010 | Lazard Capital | New Coverage | Buy (N/A) |
N/A (N/A) |
23.37 | 13.39 | -42.7% | Details |
| 12/3/2010 | Jefferies » Updated 11/9/2012 |
New Coverage | Buy (N/A) |
16.00 (21.00) |
22.66 | 13.39 | -40.91% | Details |
| 10/8/2010 | Leerink Swann » Updated 6/18/2012 |
New Coverage | Outperform (N/A) |
25.00 (N/A) |
20.37 | 13.39 | -34.27% | Details |
